てんかん市場規模・予測（2020年～2030年）、世界・地域シェア、動向、成長機会分析レポート収録範囲タイプ別（進行性ミオクロニーてんかん、反射性てんかん、全般性てんかん、その他）、投与経路別（経口剤、非経口剤、その他）、治療薬タイプ別（第一世代薬、第二世代薬、第三世代薬）、年齢層別（成人、小児）、流通チャネル別（病院薬局、小売薬局、その他）、地域別（北米、欧州、アジア太平洋地域、中東・アフリカ、南米・中米）

Epilepsy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs), Age Group (Adults and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

てんかんの市場規模は、2022年の77億米ドルから2030年には107億米ドルに成長すると予測されており、2022～2030年の年平均成長率は4.1%と予測されている。てんかんは、世界中で最も一般的な慢性神経疾患のひとつ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Insight Partners ザ・インサイトパートナーズ	2024年2月14日	US$5,190 シングルユーザライセンスライセンス・価格情報注文方法はこちら	230	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

てんかんの市場規模は、2022年の77億米ドルから2030年には107億米ドルに成長すると予測されており、2022～2030年の年平均成長率は4.1%と予測されている。
てんかんは、世界中で最も一般的な慢性神経疾患のひとつである。脳内の異常な電気的活動を伴うこの疾患は、出産適齢期の米国人女性100万人以上が罹患している。てんかんの有病率の上昇と、てんかん治療薬の開発への投資の増加は、てんかん市場規模の拡大に寄与する注目すべき要因である。抗てんかん薬（AED）の投与は通常、てんかんの第一選択治療と呼ばれている。てんかん患者の約80%は発展途上国の人々である。小児だけでなく成人においても、てんかんの治療のほとんどは薬物療法（単剤療法または併用療法）に基づいており、手術、神経調節療法、ケトジェニックダイエットなどの残りの治療アプローチが使用される頻度は低い。しかし、製品の回収がてんかん市場の成長を妨げている。

年齢層に基づく洞察
年齢層に基づき、てんかん市場は成人と小児に区分される。2022年のてんかん市場シェアは、成人が大きくなっている。さらに、2022～2030年の市場において、より高いCAGRを記録すると予測されている。てんかんは成人に発症しやすい。この疾患の危険因子は成人に多く、これには脳機能に影響を及ぼす疾患（アルツハイマー病など）、脳腫瘍、脳卒中、頭部外傷などが含まれる。米国疾病予防管理センター（CDC）によると、米国では18歳以上の成人300万人が活動性てんかんを患っています。このうち100万人近くが55歳以上である。人口の高齢化に伴い、今後さらに多くの高齢者がてんかんを患う可能性がある。2021年には、米国成人の1.1％（〜286万人）が活動性てんかんと報告されている。そのため、薬物療法や治療戦略は、この年齢層におけるてんかんの人口統計学的有病率に合わせて、成人患者を優先することが多い。

エンドユーザーに基づく洞察
てんかん市場は、流通チャネル別に病院薬局、小売薬局、その他に区分される。2022年のてんかん市場シェアは、病院薬局セグメントが最大であった。また、小売薬局セグメントは2022-2030年の間に市場で最も高いCAGRを記録すると予測されている。小売薬局店舗は、処方薬、市販薬、一部の動きの速い消費財を販売し、関連サービスを提供している。最新の小売薬局チェーンは、デジタル化、組織化、ハイテク化が進んでおり、薬の在庫を追跡し、100％信頼できる商品を販売することができる。さらに、小売薬局チェーンは、医療保険請求や保険申請を行う消費者向けに付加価値サービスを提供している。また、過去の請求書やメモの改修を依頼することもできる。さらに、患者が処方箋を記入したり、薬剤師からカウンセリングを受けたりするのに便利な場所にある。
米国疾病予防管理センター（Centers for Disease Control and Prevention）、世界保健機関（WHO）、カナダ神経保健慈善団体（Neurological Health Charities Canada）などは、てんかん市場レポート作成時に参照した一次および二次情報源のひとつである。

ページTOPに戻る

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Epilepsy Market – Key Market Dynamics
5.1 Epilepsy Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Epilepsy
5.2.2 Increasing Investments in Development of Epilepsy Therapies
5.3 Market Restraints
5.3.1 Recall of Products
5.4 Market Opportunities
5.4.1 Surge in Awareness Programs Conducted by Organizations
5.5 Future Trends
5.5.1 Gene Therapy as Promising Treatment Approach
5.6 Impact of Drivers and Restraints:
6. Epilepsy Market – Global Market Analysis
6.1 Epilepsy Market Revenue (US$ Million), 2022–2030
7. Epilepsy Market Analysis – by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8. Epilepsy Market Analysis – by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9. Epilepsy Market Analysis – by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
10. Epilepsy Market Analysis – by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11. Epilepsy Market Analysis – by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12. Epilepsy Market – Geographical Analysis
12.1 North America: Epilepsy Market
12.1.1 Overview
12.1.2 North America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.2.1 North America: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.1.2.2 North America: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.1.2.3 North America: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.1.2.4 North America: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.1.2.5 North America: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.1.3 North America: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.1.3.1 United States: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.1.1 Overview
12.1.3.1.2 United States: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.1.3 United States: Epilepsy Market Breakdown, by Type
12.1.3.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
12.1.3.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
12.1.3.1.6 United States: Epilepsy Market Breakdown, by Age Group
12.1.3.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
12.1.3.2 Canada: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.2.1 Overview
12.1.3.3 Canada: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.3.1 Canada: Epilepsy Market Breakdown, by Type
12.1.3.3.2 Canada: Epilepsy Market Breakdown, by Route of Administration
12.1.3.3.3 Canada: Epilepsy Market Breakdown, by Treatment Type
12.1.3.3.4 Canada: Epilepsy Market Breakdown, by Age Group
12.1.3.3.5 Canada: Epilepsy Market Breakdown, by Distribution Channel
12.1.3.4 Mexico: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.4.1 Overview
12.1.3.5 Mexico: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.1.3.5.1 Mexico: Epilepsy Market Breakdown, by Type
12.1.3.5.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
12.1.3.5.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
12.1.3.5.4 Mexico: Epilepsy Market Breakdown, by Age Group
12.1.3.5.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel
12.2 Europe: Epilepsy Market
12.2.1 Overview
12.2.2 Europe: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.2.1 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.2.2.2 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.2.2.3 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.2.2.4 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.2.2.5 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.2.3 Europe: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.2.3.1 United Kingdom: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.1.1 Overview
12.2.3.2 United Kingdom: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
12.2.3.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
12.2.3.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
12.2.3.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
12.2.3.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.3 Germany: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.3.1 Overview
12.2.3.4 Germany: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.4.1 Germany: Epilepsy Market Breakdown, by Type
12.2.3.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
12.2.3.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
12.2.3.4.4 Germany: Epilepsy Market Breakdown, by Age Group
12.2.3.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.5 France: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.5.1 Overview
12.2.3.6 France: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.6.1 France: Epilepsy Market Breakdown, by Type
12.2.3.6.2 France: Epilepsy Market Breakdown, by Route of Administration
12.2.3.6.3 France: Epilepsy Market Breakdown, by Treatment Type
12.2.3.6.4 France: Epilepsy Market Breakdown, by Age Group
12.2.3.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.7 Spain: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.7.1 Overview
12.2.3.8 Spain: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.8.1 Spain: Epilepsy Market Breakdown, by Type
12.2.3.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
12.2.3.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
12.2.3.8.4 Spain: Epilepsy Market Breakdown, by Age Group
12.2.3.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.9 Italy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.9.1 Overview
12.2.3.10 Italy: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.10.1 Italy: Epilepsy Market Breakdown, by Type
12.2.3.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
12.2.3.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
12.2.3.10.4 Italy: Epilepsy Market Breakdown, by Age Group
12.2.3.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
12.2.3.11 Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.11.1 Overview
12.2.3.12 Rest of Europe: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.2.3.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
12.2.3.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
12.2.3.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
12.2.3.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
12.2.3.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
12.3 Asia Pacific: Epilepsy Market
12.3.1 Overview
12.3.2 Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.2.1 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.3.2.2 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.3.2.3 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.3.2.4 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.3.2.5 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.3.3 Asia Pacific: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.3.3.1 China: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.1.1 Overview
12.3.3.2 China: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.2.1 China: Epilepsy Market Breakdown, by Type
12.3.3.2.2 China: Epilepsy Market Breakdown, by Route of Administration
12.3.3.2.3 China: Epilepsy Market Breakdown, by Treatment Type
12.3.3.2.4 China: Epilepsy Market Breakdown, by Age Group
12.3.3.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.3 Japan: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.3.1 Overview
12.3.3.4 Japan: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.4.1 Japan: Epilepsy Market Breakdown, by Type
12.3.3.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
12.3.3.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
12.3.3.4.4 Japan: Epilepsy Market Breakdown, by Age Group
12.3.3.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.5 India: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.5.1 Overview
12.3.3.6 India: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.6.1 India: Epilepsy Market Breakdown, by Type
12.3.3.6.2 India: Epilepsy Market Breakdown, by Route of Administration
12.3.3.6.3 India: Epilepsy Market Breakdown, by Treatment Type
12.3.3.6.4 India: Epilepsy Market Breakdown, by Age Group
12.3.3.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.7 Australia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.7.1 Overview
12.3.3.8 Australia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.8.1 Australia: Epilepsy Market Breakdown, by Type
12.3.3.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
12.3.3.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
12.3.3.8.4 Australia: Epilepsy Market Breakdown, by Age Group
12.3.3.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.9 South Korea: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.9.1 Overview
12.3.3.10 South Korea: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.10.1 South Korea: Epilepsy Market Breakdown, by Type
12.3.3.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
12.3.3.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
12.3.3.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
12.3.3.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
12.3.3.11 Rest of Asia Pacific: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.11.1 Overview
12.3.3.12 Rest of APAC: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.3.3.12.1 Rest of APAC: Epilepsy Market Breakdown, by Type
12.3.3.12.2 Rest of APAC: Epilepsy Market Breakdown, by Route of Administration
12.3.3.12.3 Rest of APAC: Epilepsy Market Breakdown, by Treatment Type
12.3.3.12.4 Rest of APAC: Epilepsy Market Breakdown, by Age Group
12.3.3.12.5 Rest of APAC: Epilepsy Market Breakdown, by Distribution Channel
12.4 Middle East & Africa Epilepsy Market
12.4.1 Overview
12.4.2 Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.2.1 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.4.2.2 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.4.2.3 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.4.2.4 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.4.2.5 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.4.3 Middle East and Africa: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.4.3.1 Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.1.1 Overview
12.4.3.2 Saudi Arabia: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.2.1 Saudi Arabia: Epilepsy Market Breakdown, by Type
12.4.3.2.2 Saudi Arabia: Epilepsy Market Breakdown, by Route of Administration
12.4.3.2.3 Saudi Arabia: Epilepsy Market Breakdown, by Treatment Type
12.4.3.2.4 Saudi Arabia: Epilepsy Market Breakdown, by Age Group
12.4.3.2.5 Saudi Arabia: Epilepsy Market Breakdown, by Distribution Channel
12.4.3.3 South Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.3.1 Overview
12.4.3.4 South Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.4.1 South Africa: Epilepsy Market Breakdown, by Type
12.4.3.4.2 South Africa: Epilepsy Market Breakdown, by Route of Administration
12.4.3.4.3 South Africa: Epilepsy Market Breakdown, by Treatment Type
12.4.3.4.4 South Africa: Epilepsy Market Breakdown, by Age Group
12.4.3.4.5 South Africa: Epilepsy Market Breakdown, by Distribution Channel
12.4.3.5 United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.5.1 Overview
12.4.3.6 United Arab Emirates: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.6.1 United Arab Emirates: Epilepsy Market Breakdown, by Type
12.4.3.6.2 United Arab Emirates: Epilepsy Market Breakdown, by Route of Administration
12.4.3.6.3 United Arab Emirates: Epilepsy Market Breakdown, by Treatment Type
12.4.3.6.4 United Arab Emirates: Epilepsy Market Breakdown, by Age Group
12.4.3.6.5 United Arab Emirates: Epilepsy Market Breakdown, by Distribution Channel
12.4.3.7 Rest of Middle East & Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.7.1 Overview
12.4.3.8 Rest of Middle East and Africa: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.4.3.8.1 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Type
12.4.3.8.2 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Route of Administration
12.4.3.8.3 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Treatment Type
12.4.3.8.4 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Age Group
12.4.3.8.5 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Distribution Channel
12.5 South & Central America: Epilepsy Market
12.5.1 Overview
12.5.2 South and Central America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.2.1 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Type
12.5.2.2 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Route of Administration
12.5.2.3 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Treatment Type
12.5.2.4 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Age Group
12.5.2.5 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Distribution Channel
12.5.3 South and Central America: Epilepsy Market – Revenue and Forecast Analysis – by Country
12.5.3.1 Brazil: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.1.1 Overview
12.5.3.2 Brazil: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.2.1 Brazil: Epilepsy Market Breakdown, by Type
12.5.3.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration
12.5.3.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type
12.5.3.2.4 Brazil: Epilepsy Market Breakdown, by Age Group
12.5.3.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel
12.5.3.3 Argentina: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.3.1 Overview
12.5.3.4 Argentina: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.4.1 Argentina: Epilepsy Market Breakdown, by Type
12.5.3.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration
12.5.3.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type
12.5.3.4.4 Argentina: Epilepsy Market Breakdown, by Age Group
12.5.3.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel
12.5.3.5 Rest of South & Central America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.5.1 Overview
12.5.3.6 Rest of South and Central America: Epilepsy Market – Revenue and Forecast to 2030 (US$ Million)
12.5.3.6.1 Rest of South and Central America: Epilepsy Market Breakdown, by Type
12.5.3.6.2 Rest of South and Central America: Epilepsy Market Breakdown, by Route of Administration
12.5.3.6.3 Rest of South and Central America: Epilepsy Market Breakdown, by Treatment Type
12.5.3.6.4 Rest of South and Central America: Epilepsy Market Breakdown, by Age Group
12.5.3.6.5 Rest of South and Central America: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 CombiGene AB
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 LivaNova Plc
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Medtronic Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 GSK Plc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 H. Lundbeck AS
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners

ページTOPに戻る

Table of Contents

Summary

The epilepsy market size is expected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is projected to register a CAGR of 4.1% during 2022-2030.
Epilepsy is one of the most common chronic neurological disorders across the world. Associated with an abnormal electrical activity in the brain, this disorder affects over 1 million American women of childbearing age. The rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies are noteworthy factors contributing to the expansion of the epilepsy market size. The administration of anti-epileptic drugs (AEDs) is usually referred to as the first-line treatment for epilepsy. Approximately 80% of the people suffering from epilepsy are from developing countries. In children as well as adults, the treatment of epilepsy is mostly based on the use of drugs (either in monotherapy or combined therapy), while the remaining treatment approaches, such as surgery, neuromodulation, and ketogenic diet, are used at a lesser frequency. However, the recall of products hinders the epilepsy market growth.

Age Group-Based Insights
Based on age group, the epilepsy market is segmented into adults and children. The adults segment held a larger epilepsy market share in 2022. It is further expected to register a higher CAGR in the market during 2022–2030. Epilepsy is more likely to develop in adults as some risk factors for this disease are more common in adults; these include diseases affecting brain function (such as Alzheimer’s disease), brain tumors, strokes, and head injuries. According to the Centers for Disease Control and Prevention (CDC), 3 million adults aged 18 or older are living with active epilepsy in the US. Nearly 1 million of these adults are aged 55 or older. As the population ages, even more older people are likely to suffer from epilepsy in the coming years. In 2021, 1.1% of US adults (~2.86 million adults) reported active epilepsy. Thus, medications and treatment strategies often prioritize adult patients, aligning with the demographic prevalence of epilepsy in this age group.

End User-Based Insights
Based on distribution channel, the epilepsy market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest epilepsy market share in 2022. In addition, the retail pharmacies segment is expected to register the highest CAGR in the market during 2022–2030. Retail pharmacy stores sell prescription drugs, over-the-counter drugs, and some fast-moving consumer goods, along with providing related services. Modern retail pharmacy chains are digitized, organized, and tech-enabled, which allows them to track medication inventories and sell 100% reliable goods. In addition, retail pharmacy chains provide value-added services for consumers opting for medical claims or insurance filings. They can also be requested to refurbish previous bills or memos. Moreover, their locations make them accessible for patients to fill their prescriptions and receive counseling from pharmacists.
Centers for Disease Control and Prevention, the World Health Organization, and Neurological Health Charities Canada are among the primary and secondary sources referred to while preparing the epilepsy market report.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（channel）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（channel）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?